Extend Biosciences Inc.
Newton, MA Doing business as Extend Biosciences Inc. Extend Biosciences Inc.
- UEI
- DZTKWESJQQ99
- CAGE
- 62TW2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 90 Bridge St #100, Newton, MA 02458, USA
- Website
- extendbio.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of a long-acting ghrelin derivative as a novel ALS therapeutic | Defense Health Agency | $839,497 | |
| Long-acting PTH for hypoparathyroidism - project summary hypoparathyroidism is a rare disease that results from a… | National Institute of Diabetes and Digestive and Kidney Diseases | $1,999,230 | |
| A phase 2 study investigating the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism… | FDA Office of Acquisition and Grant Services | $904,938 | |
| Army sbir phase i | ACC Aberdeen Proving Ground | $161,589 | |
| Long-acting ghrelin for neuropathy | National Institute of Neurological Disorders and Stroke | $535,325 |
About Extend Biosciences Inc.
Extend Biosciences is a clinical stage biotechnology company that develops a novel drug delivery platform technology to improve the pharmacokinetic properties of peptides and proteins. Their proprietary D VITylation® platform technology enables the efficient delivery of therapeutic peptides and proteins. Extend Biosciences is a for-profit, woman-owned, Subchapter S corporation registered to receive federal contract and grant awards.
Extend Biosciences has received a prime federal contract award from the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense. The $161,589.36 firm fixed price Purchase Order was for an Army Small Business Innovation Research (SBIR) Phase I project, which is a set-aside for small businesses. The contract was awarded on March 13, 2020 and had a completion date of September 13, 2020. The place of performance was Newton, MA 02458.
Extend Biosciences has also received multiple prime federal grant awards from agencies such as the Department of Health and Human Services Food and Drug Administration (FDA) and the National Institutes of Health National Institute of Neurological Disorders and Stroke. A notable award was a $899,808 Project Grant from the FDA (CFDA 93.103 - Food and Drug Administration Research) to conduct a Phase 2 clinical trial investigating the safety, tolerability, and efficacy of their long-acting parathyroid hormone (PTH) derivative, EXT608, for the treatment of hypoparathyroidism. The goal was to evaluate whether EXT608 can restore normal serum and urinary calcium and phosphate levels in adults with hypoparathyroidism. This award funded the double-blind, placebo-controlled Phase 2 trial, with an anticipated completion date of August 31, 2027. Extend Biosciences also received a $535,325 Project Grant from the NIH for "Long-Acting Ghrelin for Neuropathy" which was completed on August 31, 2021.
Quick answers
What is Extend Biosciences Inc.'s UEI?
Extend Biosciences Inc.'s Unique Entity ID (UEI) in SAM.gov is DZTKWESJQQ99.
What is Extend Biosciences Inc.'s CAGE code?
Extend Biosciences Inc.'s CAGE code is 62TW2.
What is Extend Biosciences Inc.'s primary NAICS code?
Extend Biosciences Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Extend Biosciences Inc. located?
Extend Biosciences Inc.'s physical address in SAM.gov is 90 Bridge St #100, Newton, MA 02458, USA.
Is Extend Biosciences Inc. registered in SAM.gov?
Yes. Extend Biosciences Inc.'s SAM.gov registration is active through April 13, 2027.
What is Extend Biosciences Inc.'s most recent federal award?
Extend Biosciences Inc.'s most recent federal grant award is Development of a long-acting ghrelin derivative as a novel ALS therapeutic (HT9425261E466), from Defense Health Agency, on September 15, 2026.
On GovTribe
See Extend Biosciences Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors